NCT03323346: Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer

NCT03323346
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03323346

Comments are closed.

Up ↑